AbbVie (ABBV), efficacité de 88 % sur 5 ans et validation de la sécurité jusqu'à 6 ans… mettant en évidence la « compétitivité à long terme » dans le traitement des maladies de la peau

艾伯维(ABBV)通过大量公布皮肤病治疗领域的长期临床数据和真实临床证据，再次凸显了其在全球市场的"可持续性"和"安全性"竞争力。
Particularly as the long-term efficacy of its main therapeutic drugs and improvements in quality of life have been simultaneously confirmed, the evaluation believes that the credibility of its entire immunology product portfolio has been further strengthened.

艾伯维宣布，将在27日至31日(当地时间)举行的2026年美国皮肤病学会(AAD)年会上发表总计24篇研究摘要。
AbbVie announced that it will present a total of 24 research abstracts at the 2026 American Academy of Dermatology (AAD) annual meeting held from the 27th to the 31st (local time).

此次发布的数据涵盖了银屑病、特应性皮炎、白癜风、斑秃等主要皮肤病领域的临床及真实诊疗数据。
The data released covers clinical and real-world treatment data in major dermatological fields such as psoriasis, atopic dermatitis, vitiligo, and alopecia areata.

最受关注的结果是银屑病治疗药物利生奇珠单抗的长期疗效。
The most noteworthy result is the long-term efficacy of the psoriasis treatment drug risankizumab.

据公司介绍，数据显示5年内无影像学疾病进展的患者比例达到88%。
According to the company, the data shows that the proportion of patients with no radiographic disease progression over 5 years reached 88%.

这是有效抑制疾病恶化的案例，是长期治疗策略中具有重要意义的一项指标。
This is a case of effectively inhibiting disease worsening and is an important indicator in long-term treatment strategies.

另一核心药物乌帕替尼基于超过9,000患者-年的数据，其安全性已确认长达6年。
Another core drug, upadacitinib, has confirmed safety for up to 6 years based on data from over 9,000 patient-years.

分析认为，由于在不同年龄段均得出一致结果，该药在真实处方环境中也有望成为稳定的选择。
Analysts believe that due to consistent results across different age groups, the drug is also expected to become a stable choice in real-world prescribing environments.

生活质量改善效果也通过数据得到证实。
The improvement in quality of life has also been confirmed through data.

皮肤病患者的生命质量指标DLQI 0/1达成率最高达88.9%，强调了临床改善为患者日常生活带来了切实变化。
The achievement rate of the quality of life index DLQI 0/1 for dermatological patients reached a maximum of 88.9%, emphasizing that clinical improvements have brought tangible changes to patients’ daily lives.

业界评价称，这"证实了其已超越单纯症状缓解，向’以患者为中心的治疗’演进"。
Industry evaluations state that this “confirms that it has transcended mere symptom relief and evolved towards ‘patient-centered treatment’.”

同时，还公布了处于3期临床试验阶段的白癜风及斑秃治疗结果。
At the same time, results for the treatment of vitiligo and alopecia areata currently in phase 3 clinical trials were also announced.

特别是乌帕替尼关于白癜风的最新研究将以"延迟发布"形式收录，预计将吸引年会现场的关注。
In particular, the latest study on vitiligo with upadacitinib will be included as a “delayed release,” which is expected to attract attention at the annual meeting.

监管方面也接连传来积极进展。
Positive developments have also been reported on the regulatory front.

利生奇珠单抗关于扩大生殖器及头皮银屑病治疗适应症的美国食品药品监督管理局(FDA)补充批准标签已获更新。
The supplemental approval label for risankizumab regarding the expanded indications for the treatment of genital and scalp psoriasis has been updated by the U.S. Food and Drug Administration (FDA).

预计此举将在拓宽治疗范围的同时，增强其市场竞争力。
This move is expected to broaden treatment options while enhancing its market competitiveness.

华尔街评价认为，艾伯维通过此次发布，其通过长期数据积累实现的"差异化战略"已变得清晰。
Wall Street evaluations suggest that AbbVie’s release has made its “differentiation strategy” achieved through long-term data accumulation clear.

一位生物科技投资专家分析称：“相较于短期效果，证明长期安全性和持续疗效已成为近期治疗药物竞争的核心”，
A biotechnology investment expert analyzed: “Compared to short-term effects, proving long-term safety and sustained efficacy has become the core of recent competition in therapeutic drugs,”

“艾伯维是在该领域拥有最前沿数据的企业之一。”
“AbbVie is one of the companies with the most cutting-edge data in this field.”

评论：此次发布不仅是一次单纯的研究结果公布，更被解读为艾伯维正在强化其在免疫疾病及皮肤病治疗市场长期主导力的信号。
Comment: This release is not just a simple announcement of research results but is interpreted as a signal that AbbVie is strengthening its long-term dominance in the immunology and dermatology treatment market.